noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Michigan Department of Transportation

Resurfacing starts on M-60, M-86 and M-99 in Calhoun and St. Joseph[...]
Clean Fuels Alliance America

Clean Fuels Welcomes Opportunity to Clarify 45Z Clean Fuel Production[...]
Office of Science and Technology[...]

Presidential Message on National Cancer Control Month

Healthcare

Cue Biopharma Inc.

04/07/2026 | Press release | Distributed by Public on 04/07/2026 06:00

Material Event (Form 8-K)

Item 8.01.

Other Events

On April 1, 2026, Cue Biopharma, Inc. (the "Company") received notice from Boehringer Ingelheim that Boehringer Ingelheim had approved selection of its first compound for lead optimization under the Collaboration and License Agreement entered into with Boehringer Ingelheim on April 10, 2025 for the research, development and commercialization of differentiated B cell depletion molecules, including the Company's CUE-501 product candidate. This preclinical milestone event triggers a $7.5 million payment to the Company, which is expected to be received in May 2026.

Cue Biopharma Inc. published this content on April 07, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 07, 2026 at 12:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]